The FDA approval of Vimkunya has given the chikungunya vaccine’s owner, Bavarian Nordic, an extra financial windfall. | The ...

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

As the country grapples with rising cases of coronavirus and mosquito-borne dengue, there has been a resurgence of another mosquito-borne disease, Chikungunya, in Dhaka.

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Local door-to-door surveys will be conducted to check for symptoms in other residents of the commune, and thorough scans of ...

Public health messaging—now focusing on Covid and dengue—should also include chikungunya, particularly its symptoms and ...

COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of ...

Dr. Harindu Wijesinghe is a medical specialist in Rheumatology and Rehabilitation, as well as in Sports Medicine. He ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Climate change is reshaping Europe’s disease landscape, with tropical mosquito-borne illnesses like dengue and chikungunya ...